CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2
2021
Hoffmann, Donata | Corleis, Björn | Rauch, Susanne | Roth, Nicole | Mühe, Janine | Halwe, Nico Joel | Ulrich, Lorenz | Fricke, Charlie | Schön, Jacob | Kraft, Anna | Breithaupt, Angele | Wernike, Kerstin | Michelitsch, Anna | Sick, Franziska | Wylezich, Claudia | Hoffmann, Bernd | Thran, Moritz | Thess, Andreas | Mueller, Stefan O. | Mettenleiter, Thomas C. | Petsch, Benjamin | Dorhoi, Anca | Beer, Martin
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding mRNA vaccines (CVnCoV and CV2CoV) against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls. mRNA-immunized mice develop elevated SARS-CoV-2 RBD-specific antibody and neutralization titers which are readily detectable, but significantly reduced against VOC B.1.351. The mRNA vaccines fully protect from disease and mortality caused by either viral strain. SARS-CoV-2 remains undetected in swabs, lung, or brain in these groups. Despite lower neutralizing antibody titers compared to the ancestral strain BavPat1, CVnCoV and CV2CoV show complete disease protection against the novel VOC B.1.351 in our studies.
Show more [+] Less [-]Bibliographic information
Publisher Nature Publishing Group
ISSN 2041-1723This bibliographic record has been provided by Friedrich-Loeffler-Institut
